Optimi Health Corp. announced the pricing of an oversubscribed public offering in connection with its uplisting to the Nasdaq Capital Market. The company is offering 2,400,000 common shares at US$6.25 per share, with expected gross proceeds of approximately US$15 million before deducting underwriting discounts and commissions. The underwriter was granted an option to purchase up to an additional 360,000 common shares. The common shares were expected to begin trading on the Nasdaq Capital Market on May 20, 2026 under the symbol “OPTH,” with the offering expected to close on or about May 21, 2026.
Use of Proceeds and Financing
The company intends to use net proceeds for scaling production and distribution of its products in current markets, additional market expansion including the United States, and sales growth and general working capital and operating expenses, though management retains broad discretion regarding actual use of the proceeds. Joseph Gunnar & Co., LLC is acting as sole book-running manager for the offering. A registration statement on Form F-1 related to the offering was declared effective by the SEC on May 19, 2026.
Share Consolidation
The company announced the record date for a previously announced consolidation of outstanding common shares on the basis of one post-consolidation common share for every 30 pre-consolidation shares, effective May 19, 2026. Following the consolidation, the company expected to have approximately 3,225,881 common shares issued and outstanding prior to giving effect to the offering. The company’s common shares were assigned a new CUSIP number (68405H308) and ISIN (CA68405H3080). The exercise price and number of common shares issuable under outstanding warrants and options were proportionately adjusted to reflect the consolidation.
Company Background
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, it produces validated MDMA and botanical psilocybin drug products at GMP-compliant facilities in British Columbia, supplying products internationally, with distribution in Australia and Canada.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.prnewswire.com/news-releases/optimi-health-announces-pricing-of-oversubscribed-us15-million-public-offering-and-nasdaq-uplisting-302777792.html